Astellas Pharma Has Announced That It Will Be Increasing Its Dividend To 37.00 - Simply Wall St
| YPH Stock | EUR 9.50 0.20 2.15% |
Roughly 55% of Astellas Pharma's stockholders are presently thinking to get in. The analysis of current outlook of investing in Astellas Pharma suggests that some traders are interested regarding Astellas Pharma's prospects. The current market sentiment, together with Astellas Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Astellas Pharma stock news signals to limit their universe of possible portfolio assets.
Astellas Pharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Astellas daily returns and investor perception about the current price of Astellas Pharma as well as its diversification or hedging effects on your existing portfolios.
Astellas |
Astellas Pharma Has Announced That It Will Be Increasing Its Dividend To 37.00 Simply Wall St
Read at news.google.com
 |
Astellas Pharma Fundamental Analysis
We analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Astellas Pharma is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Astellas Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Astellas Pharma stock to make a market-neutral strategy. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics with similar companies.
Peers
Astellas Pharma Related Equities
| BAYA | Bayer Aktiengesellscha | 5.11 | ||||
| 6MK | Merck | 3.96 | ||||
| BAYN | Bayer AG | 1.97 | ||||
| CVGU | CSPC PHARMACEUTGR | 0.87 | ||||
| RHO6 | Roche Holding | 0.24 | ||||
| AMG | Amgen | 0.16 | ||||
| JNJ | Johnson Johnson | 1.17 |
Complementary Tools for Astellas Stock analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |